+

WO2011070049A1 - Inhibiteurs de l'endothéline pour le traitement de la glomérulonéphrite à progression rapide - Google Patents

Inhibiteurs de l'endothéline pour le traitement de la glomérulonéphrite à progression rapide Download PDF

Info

Publication number
WO2011070049A1
WO2011070049A1 PCT/EP2010/069130 EP2010069130W WO2011070049A1 WO 2011070049 A1 WO2011070049 A1 WO 2011070049A1 EP 2010069130 W EP2010069130 W EP 2010069130W WO 2011070049 A1 WO2011070049 A1 WO 2011070049A1
Authority
WO
WIPO (PCT)
Prior art keywords
endothelin
inhibitor
antagonist
etb
treatment
Prior art date
Application number
PCT/EP2010/069130
Other languages
English (en)
Inventor
Pierre-Louis Tharaux
Cécile FLIGNY
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale) filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Priority to US13/513,932 priority Critical patent/US20120283190A1/en
Priority to EP10794939A priority patent/EP2509594A1/fr
Publication of WO2011070049A1 publication Critical patent/WO2011070049A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Definitions

  • the present invention relates to the use of endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis.
  • Glomerulonephritis refers to a heterogeneous group of diseases characterized by inflammatory changes in glomerular capillaries and accompanying signs and symptoms of an acute nephritic syndrome.
  • Rapidly Progressive GlomeruloNephritis also called crescentic glomerulonephritis or extracapillary glomerulonephritis
  • RPGN Rapidly Progressive GlomeruloNephritis
  • This disease is a clinical syndrome and a morphological expression of severe glomerular injury.
  • Glomerular injury manifests as a proliferative histological pattern, accumulation of T cells and macrophages, proliferation of intrinsic glomerular cells, accumulation of cells in Bowman's space (“crescents”), and rapid deterioration of renal function.
  • RPGN acute renal failure
  • RPGN kidney diseases
  • beneficial action of the blockade of endothelin receptors has been suggested from preclinical models of hypertensive or diabetic condition or nephron reduction, that are important factors in the development of glomerulosclerosis (Neuhofer W et al, 2009), and recently confirmed with short term studies in human subjects with chronic proteinuric glomerulopathies (Dhaun N et al, 2009; Weber MA et al, 2009; Wenzel RR et al, 2009) that do not correspond to the condition of RPGN.
  • RPGN is considered as a specific clinical state in which mechanisms differ from other glomerulonephritis.
  • RPGN is characterized by a proliferation of podocytes (Thorner PS et al, 2008) and parietal epithelial cells (Smeets B et al, 2009) whereas apoptosis of podocytes is generally observed in other glomerulopathies (D'Agati VD, 2008).
  • the present invention relates to an endothelin inhibitor for use in the treatment of rapidly progressive glomerulonephritis (RPGN).
  • RPGN rapidly progressive glomerulonephritis
  • the invention relates to said endothelin inhibitor in combination with an immunosuppressive treatment.
  • the invention also provides pharmaceutical compositions comprising an endothelin inhibitor of the invention.
  • the inventors showed, in an experimental model of rapidly progressive glomerulonephritis, that stimulation of endothelin receptors markedly aggravates the pathology and that blockade of endothelin receptors (ETR) prevented nephritic syndrome, infiltration of T cells and macrophages, necrotizing crescentic glomerulonephritis, acute renal failure and death, suggesting that targeting the ETR pathways would be clinically beneficial for treatment of this disease.
  • ETR endothelin receptors
  • a first object of the invention relates to an endothelin inhibitor for use in the treatment of rapidly progressive glomerulonephritis (RPGN).
  • RPGN rapidly progressive glomerulonephritis
  • Rapidly Progressive Glomerulonephritis encompasses crescentic glomerulonephritis and extracapillary glomerulonephritis.
  • treating refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • endothelin has its general meaning in the art and refers to the vasoconstricting peptide endothelin- 1 (ET-1) produced primarily in the endothelium and acting on its both receptors ETA and ETB.
  • the endothelin (ET-1) can be from any source, but typically is a mammalian (e.g., human and non- human primate) endothelin, particularly a human endothelin.
  • An exemplary native endothelin-1 amino acid sequence is provided in UniProt database under accession number P05305 and an exemplary native nucleotide sequence encoding for endothelin-1 is provided in GenBank database under accession number NM 001955.
  • ETA has its general meaning in the art and refers to the endothelin receptor type A.
  • ETA can be from any source, but typically is a mammalian (e.g., human and non-human primate) ETA, particularly a human ETA.
  • An exemplary native ETA amino acid sequence is provided in UniProt database under accession number P25101 and an exemplary native nucleotide sequence encoding for ETA is provided in GenBank database under accession number NM 001957.
  • ETB has its general meaning in the art and refers to the endothelin receptor type B.
  • ETB can be from any source, but typically is a mammalian (e.g., human and non-human primate) ETB, particularly a human ETB.
  • An exemplary native ETB amino acid sequence is provided in UniProt database under accession number P24530 and an exemplary native nucleotide sequence encoding for ETB is provided in GenBank database under accession number NM 000115.
  • endothelin inhibitor should be understood broadly and encompasses any substance able to prevent the action of endothelin (ET-1) on its receptors ETA and ETB.
  • an endothelin inhibitor encompasses an endothelin receptor antagonist of the invention, an inhibitor of endothelin, ETA or ETB gene expression and inhibitor of endothelin formation.
  • an endothelin receptor antagonist can be used.
  • endothelin receptor antagonist should be understood broadly and encompasses substances acting directly (by binding) on endothelin, ETA or ETB proteins and able to prevent the interaction or binding between endothelin and its receptor(s). So, said endothelin receptor antagonist particularly encompasses classical endothelin receptor antagonist which are small organic molecules well known in the art. Said molecules may have an antagonist effect on both ETA and ETB receptors ((ETA/ETB antagonist), or only on one of both (selective ETA receptor antagonist or a selective ETB receptor antagonist).
  • the endothelin receptor antagonist of the invention can be selected from the group consisting of: darusentan, sitaxsentan, tezosentan, bosentan, macitentan, ambrisentan, atrasentan, avosentan, clazosentan, zibotentan, edonentan, A- 182086, A- 192621 , ABT-627, BMS 193884, BQ123, BQ-788, CI1020, FR-139317, S-0139, SB-209670, TA-0201 , TAK-44, TBC371 1 , YM-598, ZD-161 1 or ZD4054.
  • said endothelin receptor antagonist is an ETA/ETB antagonist.
  • said endothelin receptor antagonist is bosentan (US5, 292,740 and US5, 883,254), described by the followin formula:
  • said endothelin receptor antagonist is a selective ETB receptor antagonist.
  • a selective ETB receptor antagonist exhibits an affinity (as expressed by dissociation constant Ki) for ETB less than about lOnM and a selectivity for ETB over ETA (as expressed by the ratio ⁇ / ⁇ ) is at least about 50.
  • ⁇ is less than 5 nM, more particularly less than 2 nM and even more particularly less than 1 Nm.
  • the ratio ⁇ ⁇ is at least about 100, more particularly about 500 and even more particularly about 1000.
  • said selective ETB receptor antagonist is BQ-788 (Okada M. et al, 2002), described by the following formula:
  • An endothelin receptor antagonist may be an antibody or antibody fragment that can partially or completely blocks the interaction between endothelin and its receptors.
  • the endothelin receptor antagonist may consist in an antibody directed against endothelin or against ETA and ETB receptors, in such a way that said antibody blocks the binding of endothelin on its receptors.
  • Antibodies directed against the endothelin or ETA/ETB receptors can be raised according to known methods by administering the appropriate antigen or epitope to a host animal selected, e.g., from pigs, cows, horses, rabbits, goats, sheep, and mice, among others.
  • a host animal selected, e.g., from pigs, cows, horses, rabbits, goats, sheep, and mice, among others.
  • Various adjuvants known in the art can be used to enhance antibody production.
  • antibodies useful in practicing the invention can be polyclonal, monoclonal antibodies are preferred.
  • Monoclonal antibodies of the invention can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture.
  • Techniques for production and isolation include but are not limited to the hybridoma technique originally described by Kohler and Milstein; the human B-cell hybridoma technique and the EBV-hybridoma technique.
  • techniques described for the production of single chain antibodies can be adapted to produce single chain antibodies of the invention.
  • Endothelin receptor antagonist useful in practicing the present invention also include antibody fragments including but not limited to F(ab')2 fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')2 fragments.
  • Fab and/or scFv expression libraries can be constructed to allow rapid identification of fragments having the desired specificity.
  • Humanized antibodies and antibody fragments thereof can also be prepared according to known techniques.
  • “Humanized antibodies” are forms of non-human (e.g., rodent) chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region (CDRs) of the recipient are replaced by residues from a hypervariable region of a non- human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity and capacity.
  • donor antibody such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity and capacity.
  • framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence.
  • the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • said endothelin receptor antagonist is an anti-endothelin antibody.
  • said endothelin receptor antagonist is an anti-ETB antibody.
  • the endothelin receptor antagonist may be an aptamer.
  • Aptamers are a class of molecule that represents an alternative to antibodies in term of molecular recognition.
  • Aptamers are oligonucleotide or oligopeptide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity.
  • Such ligands may be isolated through Systematic Evolution of Ligands by Exponential enrichment (SELEX) of a random sequence library.
  • the random sequence library is obtainable by combinatorial chemical synthesis of DNA. In this library, each member is a linear oligomer, eventually chemically modified, of a unique sequence. Possible modifications, uses and advantages of this class of molecules have been reviewed in Jayasena SD, 1999.
  • Peptide aptamers consists of a conformationally constrained antibody variable region displayed by a platform protein, such as E. coli Thioredoxin A that are selected from combinatorial libraries by two hybrid methods.
  • said endothelin inhibitor can be an inhibitor of endothelin gene expression or an inhibitor of ETA or ETB gene expression.
  • an “inhibitor of expression” refers to a natural or synthetic compound that has a biological effect to inhibit or significantly reduce the expression of a gene. Consequently an “inhibitor of endothelin gene expression” (or “inhibitor of ETA or ETB gene expression” refers to a natural or synthetic compound that has a biological effect to inhibit or significantly reduce the expression of the gene encoding endothelin (or ETA or ETB respectively).
  • Inhibitors of endothelin (or endothelin receptors) expression for use in the present invention may be based on anti-sense oligonucleotide constructs.
  • Anti-sense oligonucleotides including anti-sense RNA molecules and anti-sense DNA molecules, would act to directly block the translation of endothelin (or endothelin receptors) mRNA by binding thereto and thus preventing protein translation or increasing mRNA degradation, thus decreasing the level of endothelin, and thus activity, in a cell.
  • antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the mRNA transcript sequence encoding endothelin (or endothelin receptors) can be synthesized, e.g., by conventional phosphodiester techniques and administered by e.g., intravenous injection or infusion.
  • Methods for using antisense techniques for specifically inhibiting gene expression of genes whose sequence is known are well known in the art (e.g. see U.S. Pat. Nos. 6,566,135; 6,566,131; 6,365,354; 6,410,323; 6,107,091; 6,046,321; and 5,981,732).
  • RNAs can also function as inhibitors of endothelin (or endothelin receptors) expression for use in the present invention.
  • Endothelin (or endothelin receptors) expression can be reduced by contacting a subject or cell with a small double stranded RNA (dsRNA), or a vector or construct causing the production of a small double stranded RNA, such that endothelin expression is specifically inhibited (i.e. RNA interference or RNAi).
  • dsRNA small double stranded RNA
  • shRNAs short hairpin RNA
  • shRNAs can also function as inhibitors of endothelin (or endothelin receptors)expression for use in the present invention.
  • Ribozymes can also function as inhibitors of endothelin (or endothelin receptors) expression for use in the present invention.
  • Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
  • the mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleo lytic cleavage.
  • Engineered hairpin or hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleo lytic cleavage of endothelin (or endothelin receptors) mRNA sequences are thereby useful within the scope of the present invention.
  • ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which typically include the following sequences, GUA, GUU, and GUC. Once identified, short RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render the oligonucleotide sequence unsuitable.
  • antisense oligonucleotides and ribozymes useful as inhibitors of endothelin (or endothelin receptors) expression can be prepared by known methods. These include techniques for chemical synthesis such as, e.g., by solid phase phosphorothioate chemical synthesis.
  • anti-sense RNA molecules can be generated by in vitro or in vivo transcription of DNA sequences encoding the RNA molecule. Such DNA sequences can be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
  • suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
  • modifications to the oligonucleotides of the invention can be introduced as a mean of increasing intracellular stability and half-life.
  • Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2'-0-methyl rather than phosphodiesterase linkages within the oligonucleotide backbone.
  • Antisense oligonucleotides, siRNAs, shRNAs and ribozymes of the invention may be delivered in vivo alone or in association with a vector.
  • a "vector" is any vehicle capable of facilitating the transfer of the antisense oligonucleotide, siRNA, shRNA or ribozyme nucleic acid to the cells and preferably cells expressing endothelin (or endothelin receptors).
  • the vector transports the nucleic acid to cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector.
  • the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antisense oligonucleotide, siRNA, shRNA or ribozyme nucleic acid sequences.
  • Viral vectors are a preferred type of vector and include, but are not limited to nucleic acid sequences from the following viruses: retrovirus, such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus.
  • retrovirus such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rous sarcoma virus
  • adenovirus adeno-associated virus
  • SV40-type viruses polyoma viruses
  • Epstein-Barr viruses Epstein-Barr viruses
  • papilloma viruses herpes virus
  • vaccinia virus
  • Non-cytopathic viruses include retroviruses (e.g., lentivirus), the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes in vivo.
  • Standard protocols for producing replication-deficient retroviruses including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in 35.
  • viruses for certain applications are the adenoviruses and adeno-associated (AAV) viruses, which are double-stranded DNA viruses that have already been approved for human use in gene therapy.
  • AAV adeno-associated virus
  • AAVl to 12 AAV serotypes
  • Recombinant AAV are derived from the dependent parvovirus AAV2.
  • the adeno-associated virus type 1 to 12 can be engineered to be replication deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions.
  • the adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression characteristic of retroviral infection.
  • wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event.
  • the adeno-associated virus can also function in an extrachromosomal fashion and most recombinant adenovirus are extrachromosomal.
  • Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well known to those of skill in the art.
  • plasmid vectors have been used as DNA vaccines for delivering antigen-encoding genes to cells in vivo. They are particularly advantageous for this because they do not have the same safety concerns as with many of the viral vectors. These plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid. Some commonly used plasmids include pBR322, pUC18, pUC19, pRC/CMV, SV40, and pBlueScript, pSIREN. Other plasmids are well known to those of ordinary skill in the art.
  • Plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA. Plasmids may be delivered by a variety of parental, mucosal and topical routes.
  • the DNA plasmid can be injected by intramuscular, intradermal, subcutaneous, or other routes. It may also be administered by intranasal sprays or drops, rectal suppository and orally. It may also be administered into the epidermis or a mucosal surface using a gene-gun.
  • the plasmids may be given in an aqueous solution, dried onto gold particles or in association with another DNA delivery system including but not limited to liposomes, dendrimers, cochleate and microencapsulation.
  • the antisense oligonucleotide, siRNA, shRNA or ribozyme nucleic acid sequence is under the control of a heterologous regulatory region, e.g., a heterologous promoter.
  • said endothelin inhibitor is an inhibitor of endothelin gene expression. In another particular embodiment, said endothelin inhibitor is an inhibitor of ETB gene expression. In a further embodiment, endothelin inhibitor of the invention can be a molecule that decreases or prevents endothelin formation.
  • ECE inhibitor Endothelin-Converting Enzyme inhibitor
  • FR901533 also called WS79089B, Tsurumi Y, et al, 1994 and Tsurumi Y, et al, 1995
  • CGS 26303 De Lombaert S et al, 1994
  • Enzyme (ECE) gene expression can also be envisaged.
  • the endothelin inhibitor of the invention may be used in combination with immunosuppressive treatment for the treatment of RPGN.
  • Said immunosuppression treatment corresponds to classical immunosuppression treatment which generally consists of oral steroids in combination with oral cyclophosphamide or azathioprine.
  • a further object of the invention relates to methods and compositions for treatment of a subject afflicted with or susceptible to be afflicted with rapidly progressive glomerulonephritis (RPGN).
  • the invention relates to a method for treating RPGN comprising administering a subject in need thereof with a therapeutically effective amount of an endothelin inhibitor of the invention.
  • subject denotes a mammal, such as a rodent, a feline, a canine, and a primate.
  • a subject according to the invention is a human.
  • said inhibitor is administered in a therapeutically effective amount.
  • the invention relates to a method for treating RPGN comprising administering a subject in need thereof with a therapeutically effective amount of an endothelin inhibitor of the invention in combination with classical immunosuppressive treatment, currently used for the treatment of crescentic glomerulonephritis.
  • the endothelin inhibitor may be administered in the form of a pharmaceutical composition, as defined below.
  • the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts.
  • the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
  • the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from 1 mg to about 100 mg of the active ingredient.
  • An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
  • a further object of the invention relates to a pharmaceutical composition for treating and/or preventing RPGN, said composition comprising an endothelin inhibitor of the invention.
  • “Pharmaceutically” or “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate.
  • a pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • the endothelin inhibitor(s) may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions.
  • the active principle in the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings.
  • Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms.
  • the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
  • vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
  • These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the endothelin inhibitor of the invention can be formulated into a composition in a neutral or salt form.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active substances in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered solution thereof.
  • solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.
  • aqueous solutions For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
  • one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • the endothelin inhibitor of the invention may be formulated within a therapeutic mixture to comprise about 0.0001 to 1.0 milligrams, or about 0.001 to 0.1 milligrams, or about 0.1 to 1.0 or even about 10 milligrams per dose or so. Multiple doses can also be administered.
  • Figure 1 Effects of bosentan on albuminuria induced by experimental glomerulonephritis.
  • Figure 2 Effects of bosentan on crescentic glomerular damage.
  • Figure 3 effects of several endothelin antagonists (selective or not) on podocytes migration in vitro (BQ123 is a selective ETA antagonist; BQ788 is a selective ETB antagonist).
  • Figure 4 effect of selective ETA or ETB antagonists (BQ 123 and BQ788 respectively) on albuminuria induced by experimental glomerulonephritis
  • Figure 5 effect of selective ETA or ETB antagonists (BQ 123 and BQ788 respectively) preventing increased plasma urea concentration as an index of renal failure.
  • mice Male and female C57B1/6 mice weighing 20-25 g, 10 weeks old, purchased from Charles River France, were housed in a room with a 12 h light-dark cycle with water and food ad libido. Animal care and research protocols were in accordance with the principles and guidelines adopted by French Ministry for Agriculture. The animals were sacrificed by injection of pentobarbital (100 mg/kg i.p.)
  • mice were given bosentan, an orally active endothelin antagonist (designated chemically as 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']-bipyrimidin-4-yl]- benzenesulfonamide monohydrate).
  • bosentan an orally active endothelin antagonist
  • Each TRACLEER® 62.5 mg tablet contains 64.541 mg of bosentan, equivalent to 62.5 mg of anhydrous bosentan.
  • the chosen dose is about the maximum recommended human dose [MRHD], on a mg/m 2 basis.
  • mice were sacrificed, and blood was obtained by aortic catheterization; the kidneys were dissected out from each mouse and processed for immunohistochemistry, protein and mRNA analysis, and the remaining half-kidney fixed in 10% neutral-buffered formalin for histology.
  • Ibidi interferon-gamma
  • Ibidi's wounding inserts were used for cell migration or cell invasion studies. They are more effective than the traditional scrape method because they leave a well-defined cell free gap.
  • the inserts can be inserted into any biocompatible surface and used to culture one or multiple cell lines. These inserts have two wells that create 2 distinct cell patches with a defined gap of 500 ⁇ . The coverage of this gap after 20 hours of culture was assessed in the presence of the selective ETA antagonist BQ123 or the ETB antagonist BQ 788 (Calbiochem) or vehicle (RPMI with DMSO).
  • mice with anti-GBM serum-induced RPGN displayed marked fibrinogen deposition in glomeruli with disappearance of podocin positive podocytes. These characteristic features of severe RPGN were blunted in mice treated with an endothelin receptor antagonist, bosentan. Effects of specific ETA or ETB antagonism on experimental model of RPGN.
  • Couser WG Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant. 1998; 13 Suppl 1 : 10-5.
  • RANTES and monocyte chemoattractant protein-1 play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med. 1997;185(7):1371-1380. Neuhofer W, Pittrow D. Endothelin in human autoimmune diseases with renal involvement. Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii39-41.
  • Topham PS Csizmadia V, Soler D, Hines D, Gerard CJ, Salant DJ, Hancock WW.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des inhibiteurs de l'endothéline qui sont destinés à être utilisés dans le traitement de la glomérulonéphrite à progression rapide, ainsi que des compositions pharmaceutiques de ceux-ci.
PCT/EP2010/069130 2009-12-09 2010-12-08 Inhibiteurs de l'endothéline pour le traitement de la glomérulonéphrite à progression rapide WO2011070049A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/513,932 US20120283190A1 (en) 2009-12-09 2010-12-08 Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
EP10794939A EP2509594A1 (fr) 2009-12-09 2010-12-08 Inhibiteurs de l'endothéline pour le traitement de la glomérulonéphrite à progression rapide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306198 2009-12-09
EP09306198.4 2009-12-09

Publications (1)

Publication Number Publication Date
WO2011070049A1 true WO2011070049A1 (fr) 2011-06-16

Family

ID=42097390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/069130 WO2011070049A1 (fr) 2009-12-09 2010-12-08 Inhibiteurs de l'endothéline pour le traitement de la glomérulonéphrite à progression rapide

Country Status (3)

Country Link
US (1) US20120283190A1 (fr)
EP (1) EP2509594A1 (fr)
WO (1) WO2011070049A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053719A3 (fr) * 2011-10-11 2013-06-27 Aliophtha Ag Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels
US11491137B2 (en) 2019-12-17 2022-11-08 Chinook Therapeutics, Inc. Methods of improving renal function

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0510526A1 (fr) * 1991-04-25 1992-10-28 F.Hoffmann-La Roche & Co. Aktiengesellschaft Utilisation de sulfonamides comme médicament et nouvelles sulfonamides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5292740A (en) 1991-06-13 1994-03-08 Hoffmann-La Roche Inc. Sulfonamides
US5883254A (en) 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
WO1999032619A1 (fr) 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
WO2001036646A1 (fr) 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6573099B2 (en) 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
EP1491187A1 (fr) * 2002-03-22 2004-12-29 Kissei Pharmaceutical Co., Ltd. Agent prophylactique ou therapeutique contre des maladies renales
WO2007137980A1 (fr) * 2006-05-29 2007-12-06 Nicox S.A. Composés hétérocycliques nitrés en tant qu'antagonistes de récepteur de l'endothéline
EP1938812A1 (fr) * 2006-12-22 2008-07-02 Speedel Pharma AG Composition pharmaceutique utilisant aliskiren et avosentan

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0510526A1 (fr) * 1991-04-25 1992-10-28 F.Hoffmann-La Roche & Co. Aktiengesellschaft Utilisation de sulfonamides comme médicament et nouvelles sulfonamides
US5292740A (en) 1991-06-13 1994-03-08 Hoffmann-La Roche Inc. Sulfonamides
US5883254A (en) 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
WO1999032619A1 (fr) 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6573099B2 (en) 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
WO2001036646A1 (fr) 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
EP1491187A1 (fr) * 2002-03-22 2004-12-29 Kissei Pharmaceutical Co., Ltd. Agent prophylactique ou therapeutique contre des maladies renales
WO2007137980A1 (fr) * 2006-05-29 2007-12-06 Nicox S.A. Composés hétérocycliques nitrés en tant qu'antagonistes de récepteur de l'endothéline
EP1938812A1 (fr) * 2006-12-22 2008-07-02 Speedel Pharma AG Composition pharmaceutique utilisant aliskiren et avosentan

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
COUSER WG.: "Pathogenesis of glomerular damage in glomerulonephritis", NEPHROL DIAL TRANSPLANT., vol. 13, no. 1, 1998, pages 10 - 5
COUSER WILLIAM G: "Glomerulonephritis", LANCET (NORTH AMERICAN EDITION), vol. 353, no. 9163, 1 May 1999 (1999-05-01), pages 1509 - 1515, XP002578744, ISSN: 0099-5355 *
D'AGATI VD: "The spectrum of focal segmental glomerulosclerosis: new insights", CURR OPIN NEPHROL HYPERTENS, vol. 17, no. 3, May 2008 (2008-05-01), pages 271 - 8 1
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1999, SO RA LEE ET AL: "The effects of treatment with cyclophosphamide and methylprednisolone on expression of endothelin-1 in unilateral instillation of paraquat-induced pulmonary fibrosis in guinea pigs", XP002578743, Database accession no. EMB-1999354175 *
DE LOMBAERT S; GHAI RD; JENG AY; TRAPANI AJ; WEBB RL: "Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme", BIOCHEM BIOPHYS RES COMMUN., vol. 204, no. 1, 14 October 1994 (1994-10-14), pages 407 - 12
DHAUN N; MACINTYRE IM; MELVILLE V; LILITKARNTAKUL P; JOHNSTON NR; GODDARD J; WEBB DJ: "Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease", HYPERTENSION, vol. 54, no. 1, July 2009 (2009-07-01), pages 113 - 9
G6MEZ-GARRE D; LARGO R; LIU XH; GUTIERREZ S; LOPEZ-ARMADA MJ; PALACIOS I; EGIDO J: "An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis", KIDNEY INT., vol. 50, no. 3, September 1996 (1996-09-01), pages 962 - 72
JENNETTE JC; THOMAS DB: "Crescentic glomerulonephritis", NEPHROL DIAL TRANSPLANT, vol. 16, no. 6, 2001, pages 80 - 82
LIONAKI S; JENNETTE JC; FALK RJ: "Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis", SEMIN IMMUNOPATHOL., vol. 29, no. 4, 2007, pages 459 - 474
LLOYD CM; MINTO AW; DORF ME; PROUDFOOT A; WELLS TN; SALANT DJ; GUTIERREZ-RAMOS JC: "RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis", J EXP MED., vol. 185, no. 7, 1997, pages 1371 - 1380
NEUHOFER W ET AL: "Endothelin in human autoimmune diseases with renal involvement", RHEUMATOLOGY (OXFORD), vol. 45, no. Suppl. 3, October 2006 (2006-10-01), pages 39 - 41, XP002578742, ISSN: 1462-0324 *
NEUHOFER W; PITTROW D: "Endothelin in human autoimmune diseases with renal involvement", RHEUMATOLOGY, vol. 45, no. 3, October 2006 (2006-10-01), pages 39 - 41
NEUHOFER W; PITTROW D: "Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence", EUR J CLIN INVEST., vol. 39, no. 2, June 2009 (2009-06-01), pages 50 - 67
OKADA M; NISHIKIBE M: "BQ-788, a selective endothelin ET(B) receptor antagonist", CARDIOVASC DRUG REV., vol. 20, no. 1, 2002, pages 53 - 66
RUIZ-ORTEGA M; G6MEZ-GARRE D; LIU XH; BLANCO J; LARGO R; EGIDO J.: "Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis", J AM SOC NEPHROL., vol. 8, no. 5, May 1997 (1997-05-01), pages 756 - 68
SCHIWEK D; ENDLICH N; HOLZMAN L; HOLTHOFER H; KRIZ W; ENDLICH K: "Stable expression of nephrin and localization to cell-cell contacts in novel murine podocyte cell lines", KIDNEY INT., vol. 66, no. 1, 2004, pages 91 - 101
SMEETS B; ANGELOTTI ML; RIZZO P; DIJKMAN H; LAZZERI E; MOOREN F; BALLERINI L; PARENTE E; SAGRINATI C; MAZZINGHI B: "Renal Progenitor Cells Contribute to Hyperplastic Lesions of Podocytopathies and Crescentic Glomerulonephritis", J AM SOC NEPHROL., 19 November 2009 (2009-11-19)
TAM F W K: "Current pharmacotherapy for the treatment of crescentic glomerulonephritis", EXPERT OPINION ON INVESTIGATIONAL DRUGS 200611 GB LNKD- DOI:10.1517/13543784.15.11.1353, vol. 15, no. 11, November 2006 (2006-11-01), pages 1353 - 1369, XP002578741, ISSN: 1354-3784 *
THORNER PS; HO M; EREMINA V; SADO Y; QUAGGIN S: "Podocytes contribute to the formation of glomerular crescents", J AM SOC NEPHROL., vol. 19, no. 3, March 2008 (2008-03-01), pages 495 - 502
TOPHAM PS; CSIZMADIA V; SOLER D; HINES D; GERARD CJ; SALANT DJ; HANCOCK WW: "Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis", J CLIN INVEST., vol. 104, no. 11, 1999, pages 1549 - 1557
TSURUMI Y; FUJIE K; NISHIKAWA M; KIYOTO S; OKUHARA M: "Biological and pharmacological properties of highly selective new endothelin converting enzyme inhibitor WS79089B isolated from Streptosporangium roseum No. 79089", J ANTIBIOT (TOKYO), vol. 48, no. 2, February 1995 (1995-02-01), pages 169 - 74
TSURUMI Y; OHHATA N; IWAMOTO T; SHIGEMATSU N; SAKAMOTO K; NISHIKAWA M; KIYOTO S; OKUHARA M: "WS79089A, B and C, new endothelin converting enzyme inhibitors isolated from Streptosporangium roseum. No. 79089. Taxonomy, fermentation, isolation, physicochemical properties and biological activities", J ANTIBIOT (TOKYO), vol. 47, no. 6, June 1994 (1994-06-01), pages 619 - 30
TUBERCULOSIS AND RESPIRATORY DISEASES 1999 KR, vol. 46, no. 6, 1999, pages 775 - 785, ISSN: 0378-0066 *
WEBER MA; BLACK H; BAKRIS G; KRUM H; LINAS S; WEISS R; LINSEMAN JV; WIENS BL; WARREN MS; LINDHOLM LH: "A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial", LANCET, vol. 374, no. 9699, 24 October 2009 (2009-10-24), pages 1423 - 31
WENZEL RR; LITTKE T; KURANOFF S; JÜRGENS C; BRUCK H; RITZ E; PHILIPP T; MITCHELL A: "SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria", J AM SOC NEPHROL., vol. 20, no. 3, March 2009 (2009-03-01), pages 655 - 64

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053719A3 (fr) * 2011-10-11 2013-06-27 Aliophtha Ag Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels
CN103998609A (zh) * 2011-10-11 2014-08-20 阿里奥弗塔股份公司 通过递送人工转录因子调节受体表达
US11491137B2 (en) 2019-12-17 2022-11-08 Chinook Therapeutics, Inc. Methods of improving renal function
US11998526B2 (en) 2019-12-17 2024-06-04 Chinook Therapeutics, Inc. Methods of improving renal function
US12121509B2 (en) 2019-12-17 2024-10-22 Chinook Therapeutics, Inc. Methods of improving renal function

Also Published As

Publication number Publication date
US20120283190A1 (en) 2012-11-08
EP2509594A1 (fr) 2012-10-17

Similar Documents

Publication Publication Date Title
US9534219B2 (en) Methods of treating vascular inflammatory disorders
US9926562B2 (en) Methods for preventing and treating chronic kidney disease (CKD)
US20120070445A1 (en) Brain-derived gonadotropins and cognition
US10059946B2 (en) Method for treatment of heart failure
US20160272702A1 (en) Anti-ccl8 therapy for breast cancer
US20120283190A1 (en) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
US20230330062A1 (en) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
US20130236480A1 (en) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
WO2019207066A1 (fr) Procédés et compositions destinés au traitement du syndrome de sjögren
US20160304881A1 (en) Ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
US9212361B2 (en) Methods and pharmaceutical compositions for the treatment of hypertension
JP7580739B2 (ja) オンコスタチンｍ受容体シグナリング制御による尿路結石の予防と治療
KR20200045910A (ko) 섬유화 질환을 예방 또는 치료하는 조성물
EP2900245A1 (fr) Procédés et compositions pharmaceutiques pour le traitement de la fibrose cardiovasculaire
US20230124475A1 (en) Agents and compositions for the treatment of glioblastoma
US20220354872A1 (en) Pharmaceutical composition and use thereof for relieving progression of chronic kidney disease or preventing thereof
WO2024028476A1 (fr) Méthodes de traitement de maladies médiées par th2
EP2838542A2 (fr) Méthodes et compositions pharmaceutiques pour le traitement de l'hypertension
WO2021240519A1 (fr) Inhibiteurs de transporteurs d'acides aminés et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10794939

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010794939

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010794939

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13513932

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载